ParAllele Press Release

ParAllele BioScience, Inc. releases comprehensive non-synonymous SNP panel that can be used in disease association studies

For a wider commercial release, these products are being jointly developed by Affymetrix and ParAllele BioScience, Inc. and are currently in Early Access testing. The new standard assay panel utilizes the company's innovative MegAllele genotyping technology and Affymetrix proven GeneChip® Scanner 3000 system. "We have been using earlier versions of this highly multiplexed non-synonymous 10K cSNP panel in successful pharmaceutical collaborations and as part of our previously announced collaboration with Professor John Todd of the University's Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory at Cambridge, UK and Affymetrix", said Nick Naclerio, CEO of ParAllele BioScience, Inc. "We are excited about being able to make this new and expanded panel broadly available to the research community."

MegAllele" genotyping panels--including the new 10k cSNP panel--are available either as a service through ParAllele or, soon to be released, as MegAllele" Assay Kits distributed by Affymetrix, as per a previously announced agreement between the two companies. The 10k cSNP kits are designed to be used with a modified version of the Affymetrix GeneChip Scanner 3000. Field upgrades and full systems will be commercially available in the very near future.

ParAllele published details of the MegAllele" assay in the February 2005 issue of Genome Research. "The cSNP panel illustrates the scalability of the MegAllele" platform, providing the high levels of assay multiplexing, demanded by present day researchers who are using targeted SNPs for the screening of causative gene mutations in large association studies", said Tom Willis CSO of ParAllele BioScience, Inc.

About ParAllele Bioscience

ParAllele BioScience, Inc. is accelerating healthcare breakthroughs by providing comprehensive genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The understanding of how subtle genetic variations contribute to disease risk, prognosis and drug response will lead to new and more effective drugs, predictive diagnosis, and the ability to better tailor therapies to individual patients.

Parallele, MIP and MegAllele are trademarks of ParAllele BioScience, Inc.. All other trademarks and registered trademarks are the property of their respective owners.